228 related articles for article (PubMed ID: 9820739)
1. Molecular pathobiology of pancreatic adenocarcinoma.
Mangray S; King TC
Front Biosci; 1998 Nov; 3():D1148-60. PubMed ID: 9820739
[TBL] [Abstract][Full Text] [Related]
2. Genetic abnormalities in pancreatic cancer.
Moore PS; Beghelli S; Zamboni G; Scarpa A
Mol Cancer; 2003 Jan; 2():7. PubMed ID: 12537585
[TBL] [Abstract][Full Text] [Related]
3. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.
Loukopoulos P; Kanetaka K; Takamura M; Shibata T; Sakamoto M; Hirohashi S
Pancreas; 2004 Oct; 29(3):193-203. PubMed ID: 15367885
[TBL] [Abstract][Full Text] [Related]
4. Tumor-suppressive pathways in pancreatic carcinoma.
Rozenblum E; Schutte M; Goggins M; Hahn SA; Panzer S; Zahurak M; Goodman SN; Sohn TA; Hruban RH; Yeo CJ; Kern SE
Cancer Res; 1997 May; 57(9):1731-4. PubMed ID: 9135016
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations in pancreatic carcinoma.
Schneider G; Schmid RM
Mol Cancer; 2003 Jan; 2():15. PubMed ID: 12605716
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic adenocarcinoma: epidemiology and genetics.
Flanders TY; Foulkes WD
J Med Genet; 1996 Nov; 33(11):889-98. PubMed ID: 8950667
[TBL] [Abstract][Full Text] [Related]
7. The genetics of pancreatic cancer.
Cowgill SM; Muscarella P
Am J Surg; 2003 Sep; 186(3):279-86. PubMed ID: 12946833
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis.
Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Strzelczyk J; Janiak A; Kulig A; Malecka-Panas E
J Physiol Pharmacol; 2004 Jul; 55 Suppl 2():129-38. PubMed ID: 15608367
[TBL] [Abstract][Full Text] [Related]
9. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S
Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595
[TBL] [Abstract][Full Text] [Related]
10. [Genetics of pancreatic cancer: recent advances in molecular diagnosis].
Hayashi N; Egami H; Ogawa M
Nihon Geka Gakkai Zasshi; 2002 Jun; 103(6):476-81. PubMed ID: 12094699
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.
Moore PS; Orlandini S; Zamboni G; Capelli P; Rigaud G; Falconi M; Bassi C; Lemoine NR; Scarpa A
Br J Cancer; 2001 Jan; 84(2):253-62. PubMed ID: 11161385
[TBL] [Abstract][Full Text] [Related]
12. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.
Moore PS; Sipos B; Orlandini S; Sorio C; Real FX; Lemoine NR; Gress T; Bassi C; Klöppel G; Kalthoff H; Ungefroren H; Löhr M; Scarpa A
Virchows Arch; 2001 Dec; 439(6):798-802. PubMed ID: 11787853
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis.
Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Strzelczyk J; Janiak A; Kulig A; Malecka-Panas E
Int J Gastrointest Cancer; 2005; 35(1):33-41. PubMed ID: 15722572
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications.
Talar-Wojnarowska R; Malecka-Panas E
Med Sci Monit; 2006 Sep; 12(9):RA186-93. PubMed ID: 16940943
[TBL] [Abstract][Full Text] [Related]
15. [General rules for the study of pancreatic cancer by molecular biological aspect].
Omata M; Tada M
Nihon Geka Gakkai Zasshi; 2000 Feb; 101(2):233-6. PubMed ID: 10734643
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
17. Tumor-suppressing pathways in cystic pancreatic tumors.
Gerdes B; Wild A; Wittenberg J; Barth P; Ramaswamy A; Kersting M; Lüttges J; Klöppel G; Bartsch DK
Pancreas; 2003 Jan; 26(1):42-8. PubMed ID: 12499916
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
Salek C; Benesova L; Zavoral M; Nosek V; Kasperova L; Ryska M; Strnad R; Traboulsi E; Minarik M
World J Gastroenterol; 2007 Jul; 13(27):3714-20. PubMed ID: 17659731
[TBL] [Abstract][Full Text] [Related]
19. Mutation profile of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas.
Kannan K; Krishnamurthy J; Feng J; Nakajima T; Tsuchida N; Shanmugam G
Int J Oncol; 2000 Nov; 17(5):1031-5. PubMed ID: 11029509
[TBL] [Abstract][Full Text] [Related]
20. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas : frequent alterations in the APC/beta-catenin pathway and chromosome 11p.
Abraham SC; Wu TT; Klimstra DS; Finn LS; Lee JH; Yeo CJ; Cameron JL; Hruban RH
Am J Pathol; 2001 Nov; 159(5):1619-27. PubMed ID: 11696422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
